ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it
about
Nintedanib in NSCLC: evidence to date and place in therapyMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsFocus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCCulture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer MedicineClinical potential of gene mutations in lung cancer.Assessment of ALK gene fusions in lung cancer using the differential expression and exon integrity methods.The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR statusDevelopment of a new choroidal metastasis in resistance to crizotinib therapy in anaplastic lymphoma kinase-rearranged non-small cell lung cancerDown-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.A new look at the ALK gene in cancer: copy number gain and amplification.Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy.Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.Highlights from the Literature.
P2860
Q26745424-A38B148F-43C5-42AC-A4B5-D7F9A0D2A5E5Q26769659-5A0490BB-CF39-4EF9-B02D-9B8228B259F7Q28068643-EA9F59BD-D706-42F4-B91B-06CB12BA0FD9Q28553627-80F36E04-B200-47B7-AEFE-1A874C6251A7Q36316009-37A1F170-5C4F-4C41-ACB3-D0BCFFC5A473Q36640731-1476DCE2-1338-48E5-A740-41770F6121A6Q37392573-4F3086AD-EF82-4AEB-B803-84ECA435CDB1Q37647848-6CD8BA6A-EFE6-43E6-AD0B-6A807497D2B6Q37728684-C091B826-C3E6-449A-B8E5-027AFD3D6BF1Q38760747-00C276B9-9FDC-4134-99FA-BCF18C3FBB0AQ38767073-EE7F3A36-9975-4177-B542-2DD0016ECCCEQ42697768-AC02ECD2-B7AF-48DF-8062-AD2E31BE59A2Q47113459-B1951474-0D5C-4B9C-BDC1-0FDF30FC91C8
P2860
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
ALK and crizotinib: after the ...... d new therapies to overcome it
@ast
ALK and crizotinib: after the ...... d new therapies to overcome it
@en
ALK and crizotinib: after the ...... d new therapies to overcome it
@nl
type
label
ALK and crizotinib: after the ...... d new therapies to overcome it
@ast
ALK and crizotinib: after the ...... d new therapies to overcome it
@en
ALK and crizotinib: after the ...... d new therapies to overcome it
@nl
prefLabel
ALK and crizotinib: after the ...... d new therapies to overcome it
@ast
ALK and crizotinib: after the ...... d new therapies to overcome it
@en
ALK and crizotinib: after the ...... d new therapies to overcome it
@nl
P2093
P2860
P50
P3181
P1476
ALK and crizotinib: after the ...... d new therapies to overcome it
@en
P2093
Annemieke De Wilde
Antonio Russo
Christian Rolfo
Francesco Passiglia
Giuseppe Bronte
Jan P Van Meerbeeck
Karen Zwaenepoel
Luis E Raez
Patrick Pauwels
Paul Germonpre
P2860
P304
P3181
P356
10.3978/J.ISSN.2218-6751.2014.03.01
P407
P577
2014-08-01T00:00:00Z